Laura Davis
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 377 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 34 manufacturers reported payments, led by Medtronic at 44.7% of the total. Among medical clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 377 payments — averaging $21.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$4K
- AbbVie$1K
- Boston Scientific$759
- Collegium Pharmaceutical, Inc.$733
- Pfizer$180
- Johnson & Johnson$178
- plus $1K from 28 others
What the payments were for
- Food & beverage$8,106100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 113 | $3,625 |
| AbbVie(2 entities) | 91 | $1,137 |
| Boston Scientific | 16 | $759 |
| Collegium Pharmaceutical, Inc. | 72 | $733 |
| Pfizer | 10 | $180 |
| Johnson & Johnson | 9 | $178 |
| Merz Pharmaceuticals, LLC | 6 | $170 |
| Si-bone, Inc. | 6 | $148 |
| Merck | 6 | $103 |
| Teva Pharmaceuticals USA, Inc. | 5 | $100 |
| Amgen | 5 | $99 |
| Vertex | 4 | $97 |
| Vertos Medical, Inc. | 1 | $95 |
| Pacira Pharmaceuticals Incorporated | 3 | $84 |
| Lundbeck LLC | 3 | $63 |
| Curonix LLC | 2 | $52 |
| SPR Therapeutics, Inc | 2 | $49 |
| Pacira Therapeutics, Inc. | 2 | $45 |
| Nevro Corp. | 2 | $42 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $37 |
| Avanos Medical | 2 | $34 |
| Acacia Pharma Inc | 2 | $33 |
| Biohaven Pharmaceuticals, Inc. | 1 | $31 |
| Hikma Pharmaceuticals USA | 2 | $27 |
| Averitas Pharma Inc. | 1 | $26 |
| Tersera Therapeutics LLC | 1 | $23 |
| Bioventus LLC | 1 | $23 |
| Scilex Pharmaceuticals Inc. | 1 | $22 |
| Redhill Biopharma Inc. | 1 | $19 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Impel Pharmaceuticals Inc. | 1 | $15 |
| Abbott | 1 | $15 |
| Lilly USA, LLC | 1 | $14 |
| Biogen | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTELLIS ADAPTIVESTIM$738
- Intracept$430
- VANTA ADAPTIVESTIM$245
- INTELLIS$225
- INCEPTIV$160
How this compares
$8,106 in reported general payments places this provider in the 90th percentile of 632 medical providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 228 | $152,334 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 2,711 | $76,053 |
| Oxycodone Hcl | 2,628 | $70,306 |
| PercocetOxycodone Hcl/Acetaminophen | 13 | $69,272 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 1,678 | $64,506 |
| BelbucaBuprenorphine Hcl | 71 | $60,065 |
| OxycontinOxycodone Hcl | 99 | $54,833 |
| Fentanyl | 260 | $40,905 |
| Oxymorphone Hcl ErOxymorphone Hcl | 21 | $37,476 |
| Buprenorphine | 98 | $30,677 |
| Nurtec OdtRimegepant Sulfate | 11 | $22,153 |
| QuliptaAtogepant | 17 | $18,166 |
| LinzessLinaclotide | 28 | $15,480 |
| Morphine Sulfate ErMorphine Sulfate | 484 | $15,119 |
| Gabapentin | 1,092 | $14,593 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca | $733 | $212,399299 claims |
| Hikma Pharmaceuticals USABuprenorphine, Buprenorphine-Naloxone, Morphine Sulfate | $27 | $42,735281 claims |
| AbbVieQulipta, Linzess | $1,137 | $33,64645 claims |
| PfizerNurtec Odt | $180 | $22,15311 claims |
| Redhill Biopharma Inc.Movantik | $19 | $5,39613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 632 medical providers in Virginia.
Other medical in Salem
- Dana AdamsSalem$13K
- Bryan UrquhartFredericksburg$264K
- Sara VillalonaRichmond$240K
- Sarah SafaLansdowne$171K
- Waseem GarbiaFairfax$114K
- Rana HassanAshburn$54K
- Brian LamFalls Church$42K
- Christine KesslerKing George$20K
- Janlyn AnthonyRichmond$18K
- Cara DepanfilisNorfolk$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.